The 2016 WHO classification of central nervous system tumors: what neurologists need to know
|
|
- Melinda Rose
- 5 years ago
- Views:
Transcription
1 REVIEW C URRENT OPINION The 2016 WHO classification of central nervous system tumors: what neurologists need to know John C. DeWitt a,, Andreas Mock a,b,c,, and David N. Louis a Purpose of review The 2016 WHO classification of tumors of the central nervous system (2016 CNS WHO) features many changes that are relevant to neurologists treating patients with brain tumors as well as neurologists involved in basic, clinical, and epidemiological research. This review summarizes what neurologists need to know and will need to know in the next years. Recent findings The 2016 CNS WHO introduces diagnostic terms that integrate histological and molecular information and suggests presenting diagnoses in a four-layered reporting format. In addition, it utilizes a not otherwise specified designation to identify diagnostic categories that are not precisely defined. A better understanding of the biology of entities further led to changes in the tumor nosology, for example, diffuse gliomas based on IDH gene status. Meaningful molecular subgroups could also be identified in embryonal tumors and other entities. Given the pace of change in the field of brain tumor classification, there will likely be additional practical advances that emerge over the next few years. A new initiative entitled Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy intends to formulate recommendations between WHO updates. Summary The 2016 CNS WHO includes major changes in the way brain tumors are classified, with molecular parameters being incorporated into diagnostic criteria for a substantial number of such entities. Keywords brain tumors, glioma, WHO INTRODUCTION The 2016 WHO classification of tumors of the central nervous system (2016 CNS WHO) is markedly different from its 2007 predecessor, with major changes relevant to neurologists treating patients with brain tumors as well as neurologists involved in basic, clinical, and epidemiological research [1 ]. The current review outlines those changes and adumbrates additional developments likely to affect brain tumor classification over the next few years (see Table 1 for a summary of the major changes). BASIC PRINCIPLES The 2016 CNS WHO differs from the past four CNS WHO classifications in that, in addition to adding and deleting histologically defined tumor entities just as the 1979, 1993, 2000, and 2007 classifications did, it also formulates tumor entities on the basis of both histological and molecular grounds. Prior to incorporating molecular parameters into tumor classification, the WHO Working Group had access to the results of two surveys with good response rates that supported the decision to incorporate molecular characteristics into the classification: one to the Society for Neuro-Oncology and one to the International Society of Neuropathology (ISN). The Society for Neuro-Oncology survey, with about 400 respondents that covered the breadth of neurooncological disciplines, demonstrated that all specialties believed that the field had progressed to the point at which use of molecular diagnostic a Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA, b Division of Experimental Neurosurgery, Department of Neurosurgery and c Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany Correspondence to David N. Louis, MD, Room 225, Warren Building, 55 Fruit Street, Boston, MA 02114, USA. Tel: ; dlouis@mgh.harvard.edu John C. DeWitt and Andreas Mock contributed equally to this article. Curr Opin Neurol 2017, 30: DOI: /WCO Copyright ß 2017 Wolters Kluwer Health, Inc. All rights reserved.
2 Neoplasms KEY POINTS The 2016 WHO classification formulates tumor entities based on both histological and molecular information. Neurologists should familiarize themselves with the layered diagnostic report formats, the use of integrated diagnoses and NOS designations. The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy initiative was formed to publish recommendations as new molecular knowledge about CNS tumors emerges. approaches was warranted [2 ]. The ISN survey, with approximately 300 respondents from 50 countries, showed that the availability of both immunohistochemical and molecular capabilities was widespread, and that most pathologists in nearly all countries has some access to the relevant technologies [3 ]. Nonetheless, given the marked conceptual difference, the 2016 CNS WHO relied on a variety of approaches not taken by the prior classifications, notably the use of integrated diagnoses, layered diagnostic report formats [4 ], nosological reconfigurations based on biological understandings, and more liberal use of the not otherwise specified (NOS) designation. Table 1. Summary of the major changes in the 2016 central nervous system WHO that neurologists need to know Formulating concept of how CNS tumor diagnoses are structured in the molecular era Major restructuring of diffuse gliomas, with incorporation of genetically defined entities Major restructuring of medulloblastomas, with incorporation of genetically defined entities Major restructuring of other embryonal tumors, with incorporation of genetically defined entities and removal of the term primitive neuroectodermal tumor Incorporation of a genetically defined ependymoma variant IDH wild-type and IDH-mutant glioblastoma (entities) Diffuse midline glioma, H3 K27M-mutant (entity) Epithelioid glioblastoma (variant) Glioblastoma with primitive neuronal component (pattern) Addition of brain invasion as a criterion for atypical meningioma Restructuring of solitary fibrous tumor and hemangiopericytoma (SFT/HPC) as one entity and adapting a grading system to accommodate this change Integrated diagnoses The 2016 CNS WHO attempts to classify tumors on the basis of both histological and molecular parameters, at least for those tumors for which there is clinically and biologically relevant known molecular information. To do so, it has followed the socalled ISN-Haarlem guidelines and the approaches used by the hematological malignancy classification community: the use of diagnostic terms that integrate histological and molecular information. For example, tumor entities such as diffuse gliomas are designated both by their histological and molecular features, for example, diffuse astrocytoma, IDHmutant. In other words, the official WHO designation is no longer simply diffuse astrocytoma. Layered diagnoses The ISN-Haarlem guidelines proposed a four-layered reporting format that allows preservation of a traditional histological diagnosis and histological grade in addition to listing of molecular information and generation of an integrated diagnosis (Table 2). It is important for neurologists to be aware of this format as they will likely see diagnoses being rendered in this format. It is also essential to realize that, because the molecular information may only come back after a few days to weeks, the integrated diagnosis may appear after the original histological diagnosis, meaning that the pathologist may render an integrated diagnosis of pending prior to the molecular information being available. Such an approach makes it clear that an integrated diagnosis will be rendered, and is far safer than including the integrated diagnosis in an addendum that may or may not be seen weeks after the original diagnosis. The layered diagnosis is thus a safety feature in the era of molecular classification. Paradigm shifts in tumor nosology Basing diagnoses on biological relationships in addition to histological similarities has required some Table 2. Layered diagnosis of central nervous system tumors Integrated diagnosis Histological diagnosis Histological grade Molecular information An abbreviated summary of major changes in the 2016 CNS WHO that are most relevant to the practicing neurologist. CNS, central nervous system. Adapted with permission [1 ]. The layered diagnosis format from the ISN-Haarlem guidelines. The top-line integrated diagnosis incorporates all aspects of the histologic and molecular findings in the layers below. Adapted with permission [4 ]. 2 Volume 30 Number 00 Month 2017
3 WHO classification of central nervous system tumors DeWitt et al. notable shifts in the overall organization of the classification. The most notable examples of this are closer grouping of all diffuse gliomas (whether astrocytic or oligodendroglial in appearance) based on IDH gene status rather than closer grouping of gliomas with an astrocytic phenotype, and the use of both histological subdivisions as well as genetic subdivisions of medulloblastomas. Expressing uncertainty and not otherwise specified diagnoses Because specific combined histological and molecular information may not be available for a certain tumor or tumor type, the 2016 CNS WHO utilizes the NOS designation to identify those diagnostic categories that are not precisely defined. An NOS designation implies that there is insufficient information to assign a more specific code. NOS suffixes (e.g., diffuse astrocytoma, NOS) have been added to the classification in those places where such diagnoses are possible. NOS in general refers to tumors that have not been fully tested for the key genetic features, but may also include lesions that have been tested but do not show the diagnostic genetic alterations. Most important to realize is that the NOS diagnosis does not define a specific entity; rather it designates a group of lesions that cannot be classified into the more precisely defined groups. These entities require further study prior to the next WHO classification. WHAT THE NEUROLOGIST NEEDS TO KNOW Diffuse gliomas One of the major areas in which the new classification incorporates both histologic and genetic characteristics is the diffuse gliomas (Fig. 1). The presence or absence of IDH1 and IDH2 gene mutations now separates astrocytomas and glioblastoma into IDH-mutant and IDH-wildtype categories. Genetic features are also required for the diagnosis of the common type of oligodendroglioma: in addition to IDH mutation, combined whole arm losses of the short (p) arm of chromosome 1 and the long (q) arm of chromosome 19 (1p/19q codeletion) are necessary. In the absence of documentation of IDH mutation or 1p/19q codeletion, only a diagnosis of oligodendroglioma, NOS is possible. These new classifications not only separate entities in a more logical manner based on their phenotype and genotype, but also into groups that share similar prognostic outcomes and treatment strategies. For IDH, approximately 90% of mutations occur in the form of the R132H IDH1 variant, a variant reliably screened for by use of R132H-IDH1-specific Astrocytoma Oligoastrocytoma Oligodendroglioma IDH-mutant IDH-wildtype ATRX loss* TP53 muta on* Diffuse astrocytoma, IDH-mutant 1p/19q codele on Oligodendroglioma, IDH-mutant and 1p/19q-codeleted Diffuse astrocytoma, IDH-wildtype / Oligodendroglioma, NOS Gene c tes ng not done or inconclusive Glioblastoma, IDH-mutant Glioblastoma Glioblastoma, IDH-wildtype Diffuse astrocytoma, NOS Oligodendroglioma, NOS Oligoastrocytoma, NOS Glioblastoma, NOS FIGURE 1. The 2016 central nervous system WHO classification uses histological features, IDH status and other genetic parameters to classify the diffuse gliomas. ATRX loss or TP53 mutation are not required for diagnosis, but are characteristic. Adapted with permission [11]. NOS, not otherwise specified Copyright ß 2017 Wolters Kluwer Health, Inc. All rights reserved. 3
4 Neoplasms immunohistochemistry (IHC). In those cases that do not stain for R132H IDH1, the 2016 WHO recommends evaluation of all grade II and grade III astrocytomas and oligodendrogliomas with sequencing to look for noncanonical IDH1 and IDH2 mutations. However, because of the rare occurrence of noncanonical IDH1 and IDH2 mutations in older glioblastoma patients, sequencing of an R132H IDH1 immunonegative result is only recommended in patients less than 55 years of age [5,6 ]. In addition to these major changes in the more common diffuse gliomas, there are new approaches to some rarer types. Epithelioid glioblastoma is now a recognized variant of IDH-wildtype glioblastoma that often harbors a BRAFV600E mutation, making recognition of this subtype and its potentially targetable mutation an important part of glioblastoma evaluation and possibly treatment [7]. Glioblastoma with primitive neuronal component was added as a clinically relevant pattern to recognize in glioblastoma, as these tumors are prone to craniospinal fluid dissemination and therefore from a clinical perspective may prompt evaluation of the craniospinal axis for tumor seeding [8]. A new entity in the 2016 WHO is the diffuse midline glioma, H3 K27Mmutant. This diffusely infiltrating tumor often found in a midline location [spinal cord, brain stem (i.e., what used to be termed diffuse intrinsic pontine glioma or brain stem glioma), or thalamus] occurs primarily in pediatric patients and is characterized by mutation of the histone H3 gene H3F3A [9]. Knowledge of genetically defined entities such as these is important as they represent unique opportunities for possible therapeutic targeting and involvement in clinical trials. Embryonal tumors The classification of embryonal tumors, including medulloblastomas, has undergone substantial changes with the incorporation of genetic information into tumor classification. There has long been prognostic implications of the different histologic subtypes of medulloblastoma, and with advances in molecular techniques, there are now generally accepted genetic subtypes with their own prognostic and therapeutic implications [10]. In the 2016 WHO, rather than list all the possible combinations of histologic and genetic subtypes, two categories of variants of medulloblastoma are listed: those histologically defined and those genetically defined, with the expectation that the pathologist will communicate both pieces of information in an integrated diagnostic format (see Table 3). Advances in molecular information have also led to the consolidation of a number of rare Table WHO classification of medulloblastomas Medulloblastomas, genetically defined Medulloblastoma, WNT-activated Medulloblastoma, SHH-activated and TP53-mutant Medulloblastoma, SHH-activated and TP53-wildtype Medulloblastoma, non-wnt/non-shh Medulloblastoma, group 3 Medulloblastoma, group 4 Medulloblastomas, histologically defined Medulloblastoma, classic Desmoplastic/nodular medulloblastoma Medulloblastoma with extensive nodularity Large cell/anaplastic medulloblastoma Medulloblastoma, NOS Genetically and histologically defined medulloblastomas. Genetic and histologic diagnoses come together to form a single integrated diagnosis. NOS, not otherwise specified. Adapted with permission [11]. embryonal tumors, as it has become increasingly recognized that many of these tumors harbor amplifications of the C19MC region on chromosome 19. These tumors include the former embryonal tumor with abundant neuropil and true rosettes, ependymoblastoma, and most medulloepitheliomas, now collectively known in the 2016 WHO as embryonal tumor with multilayered rosettes, C19MC-altered. Furthermore, atypical teratoid/rhabdoid tumor is now defined by loss of expression of INI-1, or more rarely BRG-1, with both alterations able to be screened for by IHC [12]. In those tumors lacking this genetically defined characteristic, the term CNS embryonal tumor with rhabdoid features is now used. Other neoplasms The incorporation of advances in the molecular understanding of CNS tumors has not only impacted diffuse gliomas and embryonal tumors. Among ependymomas, a genetically defined entity, ependymoma, RELA-fusion-positive is now recognized [13,14]. Although the classification of meningiomas was largely unchanged, the presence of brain invasion was added as a sufficient criterion for classification as a WHO grade II atypical meningioma, as clinical outcomes such as recurrence and mortality rate are known to be poorer in these cases compared with grade I meningiomas [15]. Another entity undergoing changes in the 2016 WHO is the newly combined entity of solitary fibrous tumor (SFT)/haemangiopericytoma (HPC). These entities share the same genetic alteration, with fusion of the NAB2 and signal transducer 4 Volume 30 Number 00 Month 2017
5 WHO classification of central nervous system tumors DeWitt et al. and activator of transcription (STAT)6 genes leading to accumulation of STAT6 protein in the nucleus, and likely represent a spectrum along a single entity [16]. Given the spectrum of clinical behavior inherent in this new single entity, grading breaks from the traditional grading of CNS neoplasms with three distinct grades (WHO grade I, II, and III) within this single entity. Clinically, grade I lesions should be expected to behave more similar to the historically defined SFT, grade II lesions to historically defined HPC, and grade III lesions to historically defined anaplastic HPC. WHAT THE NEUROLOGIST WILL NEED TO KNOW Grading astrocytomas The 2007 CNS WHO divided diffuse gliomas into grades II, III, and IV based on histological features because all prior studies had been based on histological grading systems. As such, it is unclear whether such grades are accurate estimates for combined histological and molecular classifications; in other words, grades need to be redefined by repartitioning cohorts according to the 2016 CNS WHO integrative diagnosis. Most strikingly, work in astrocytomas suggests that the former prognostic differences were primarily because of different distributions of IDH mutations. Notably, the prognosis of IDH-mutant astrocytomas appears to be more favorable than their wild-type counterparts. Within the IDH-mutant group, however, virtually no survival difference could be observed between grade II, III, and IV tumors [17,18 ]. In addition, mitotic index, which has been a key feature for histological grading, could not be confirmed as prognostic in IDH-mutant astrocytomas [19]. In IDH-wildtype astrocytomas, grade II and IV tumors were found to be distinct regarding overall survival, but not grade III and IV tumors [18 ], suggesting that IDH-wildtype anaplastic astrocytomas might be undersampled IDH-wildtype glioblastomas. Nonetheless, not all studies have found such discrepancies [20] and the 2016 CNS WHO did not feel that there was sufficient evidence to change grading at this time, but a recasting of prognostic grades is likely in the near future and will have a major impact on treatment regimes and clinical trials. Pediatric low-grade glioma Seminal work over the past few years has shown that the majority of pediatric low-grade gliomas harbor a genetic alteration in the mitogen-activated protein kinase pathway (reviewed in [21 ]). Although current histological groupings fail to capture the observed molecular heterogeneity, some histological entities are enriched for particular molecular alterations (e.g., BRAF alterations in pilocytic astrocytomas) and it is, therefore, expected that employing an integrative diagnosis as suggested by the ISN-Haarlem guidelines [4 ]willbe instrumental in defining entities in the near future. Given the current evidence for putatively targetable alterations, a basic molecular workup currently includes assessments for BRAF V600E mutation and BRAF fusion, but this list could grow quickly in the future and the list of assayed genes is already much longer at pediatric brain tumor centers. Ependymoma Histological grading of ependymoma has been controversial, without consistent prognostic capability and confounded by the anatomical location of the tumor. Hence, the current consensus on the clinical management of ependymomas is to refrain from grading-based treatment decisions [22 ]. Instead, nine molecular subgroups have been proposed with three entities per location (supratentorial, posterior fossa, and spine); this approach outperforms histological grading with respect to risk stratification [23]. One supratentorial ependymoma group could be identified to harbor a RELA fusion protein and is already included in the 2016 CNS WHO; another is tightly associated with a YAP1 fusion protein. With these changes in classification, clinical studies will need to identify entity-specific treatment recommendations. Meningioma The current WHO grading of meningiomas based on histopathology has been imperfect in predicting the 20% of tumors that recur and prognostic biomarkers are yet to be established [24 ]. A comprehensive recent study suggests that meningiomas can be more accurately stratified for clinical behavior by DNA methylation profiling [25 ]. Critically assessing the feasibility of DNA methylation profiling in routine pathology workups will be instrumental to determine its role for clinical decision-making in the next years. Consortium to Inform Molecular and Practical Approaches to Central Nervous System Tumor Taxonomy The current pace of identifying genetic alterations in human brain tumors and understanding their Copyright ß 2017 Wolters Kluwer Health, Inc. All rights reserved. 5
6 Neoplasms clinical correlates is faster than the cycle of WHO classifications, as WHO classifications relate to a wide variety of clinical, experimental, and epidemiological stakeholders [1,4 ] and therefore cannot be updated too frequently. For example, extensions of the diagnostic algorithm for diffuse glioma by ATRX and TERT [26] mutation status and the definition of new pediatric tumor entities [27 ] have been proposed very recently. As a result, a new initiative has begun, entitled the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (or cimpact) [28,29]. This is not an official WHO process, but is intended to complement the longer interval WHO updates. cimpact has recently begun and intends to publish consensus recommendations on some of the upcoming challenges mentioned above. CONCLUSION The 2016 CNS WHO represents a large step forward in CNS tumor classification, both from conceptual and practical points of view, and features many changes that neurologists should understand. Nonetheless, with the rapid ongoing changes in the field, it is likely that neurologists will also need to be attentive to practical advances in brain tumor classification that emerge over the next few years, potentially well ahead of future WHO classifications. Acknowledgements None. Financial support and sponsorship None. Conflicts of interest There are no conflicts of interest. REFERENCES AND RECOMMENDED READING Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest 1. LouisDN, PerryA, ReifenbergerG, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica 2016; 131: Summary of the 2016 WHO classification of CNS tumors. 2. Aldape K, Nejad R, Louis DN, Zadeh G. Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. Neuro Oncol 2017; 19: The publication summarizes the results of a survey of the neuro-oncology community regarding the integration of molecular markers into neuropathologic diagnoses. This survey showed strong support for the integration of molecular markers into the CNS WHO, and the layered diagnostic format. 3. Andreiuolo F, Mazeraud A, Chrétien F, Pietsch T. A global view on the availability of methods and information in the neuropathological diagnostics of CNS tumors: results of an international survey among neuropathological units. Brain Pathol 2016; 26: The publication shows the availability of molecular methods and the use of biomarkers for brain tumor diagnostics across 48 countries. 4. Louis DN, Perry A, Burger P, et al., International Society of Neuropathology: Haarlem. International Society of Neuropathology: Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014; 24: The publication proposed guidelines for the molecular classification of brain tumors as well as a layered reporting system for brain tumor diagnoses. 5. Chen L, Voronovich Z, Clark K, et al. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 2014; 16: Robinson C, Kleinschmidt-DeMasters BK. IDH1-mutation in diffuse gliomas in persons age 55 years and over. J Neuropathol Exp Neurol 2017; 76: The publication supports the hypothesis that although the frequency of IDH mutations are low in patients 55 and over, the frequency of R132H-IDH1 mutations detectable by IHC in this population warrants screening. 7. Broniscer A, Tatevossian RG, Sabin ND, et al. Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol 2014; 40: Perry A, Miller CR, Gujrati M, et al. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol 2009; 19: Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012; 124: Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012; 123: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. World Health Organization Histological Classification of Tumours of the Central Nervous System (Revised 4th edition). Lyon: International Agency for Research on Cancer; Biegel JA. Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus 2006; 20:E Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95-RELA fusions drive oncogenic NF-kB signalling in ependymoma. Nature 2014; 506: Pietsch T, Wohlers I, Goschzik T, et al. Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-kB signaling pathway. Acta Neuropathol 2014; 127: Perry A, Stafford SL, Scheithauer BW, et al. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 1997; 21: Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 2013; 125: Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 2015; 129: Tabouret E, Nguyen AT, Dehais C, et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 2016; 132: The publication reclassifies a large French cohort of cases with high-grade glioma according to the 2016 WHO classification and shows there is significantly greater prognostic value in the updated classification when incorporating molecular information. 19. Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 2015; 129: Killela PJ, Pirozzi CJ, Healy P, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 2014; 5: Packer RJ, Pfister S, Bouffet E, et al. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol 2017; 19: The publication summarizes the findings of a consensus conference on the impact of molecular genetics on pediatric low-grade glioma diagnosis and treatment. Recommendations for integration of molecular information into diagnoses and treatment are supported. 22. Pajtler KW, Mack SC, Ramaswamy V, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 2017; 133:5 12. The publication suggests treatment for ependymoma (outside of clinical trials) should be independent of grade, and that molecular subgrouping should be a part of all subsequent clinical trials. 23. Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015; 27: Volume 30 Number 00 Month 2017
7 WHO classification of central nervous system tumors DeWitt et al. 24. Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 2016; 17:e383 e391. The publication reviews the evolving strategies for diagnosis and treatment of meningiomas, including surgery, radiosurgery, radiotherapy, and emerging pharmacologic approaches. 25. Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 2017; 18: The publication suggests that meningiomas can be more accurately stratified using DNA methylation profiling. 26. Pekmezci M, Rice T, Molinaro AM, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 2017; 133: Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 2016; 164: The publication shows molecular profiling can identify well defined CNS-PNET entities and identifies four novel entities based on their unique molecular profiles. 28. Louis DN, Aldape K, Brat DJ, et al. cimpact-now (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol Louis DN, Aldape K, Brat DJ, et al. Announcing cimpact-now: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol 2017; 133: Copyright ß 2017 Wolters Kluwer Health, Inc. All rights reserved. 7
Gliomas in the 2016 WHO Classification of CNS Tumors
Gliomas in the 2016 WHO Classification of CNS Tumors Hindi N Al-Hindi, MD, FCAP Consultant Neuropathologist and Head Section of Anatomic Pathology Department of Pathology and Laboratory Medicine King Faisal
More informationPr D.Figarella-Branger Service d Anatomie Pathologique et de Neuropathologie, La Timone, Marseille UMR 911 Inserm, Université d Aix-Marseille
Novelties in the WHO 2016 classification of brain tumours Pr D.Figarella-Branger Service d Anatomie Pathologique et de Neuropathologie, La Timone, Marseille UMR 911 Inserm, Université d Aix-Marseille The
More informationWHO 2016 CNS Tumor Classification Update. DISCLOSURES (Arie Perry, MD) PATTERN RECOGNITION. Arie Perry, M.D. Director, Neuropathology
WHO 2016 CNS Tumor Classification Update Arie Perry, M.D. Director, Neuropathology DISCLOSURES (Arie Perry, MD) I have no financial relationships to disclose. - and - I will not discuss off label use or
More informationThe New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas
The New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas Stefan Prokop, MD Neuropathology Fellow Hospital of the University of Pennsylvania Background
More informationAnnouncing cimpact-now: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 Announcing cimpact-now: the Consortium to Inform Molecular and Practical
More informationNeuropathology Evening Session: Case 3
Neuropathology Evening Session: Case 3 Christine E. Fuller, MD Cincinnati Children s Hospital Medical Center Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position
More informationUpdates on the CNS classifica3on of brain tumors
27 th Annual Mee-ng of the IAP-AD "New Horizons in Surgical Pathology Conrad Dubai, UAE Friday, 27 November 2015 Updates on the CNS classifica3on of brain tumors Eyas M Ha=ab, MD Department of Pathology
More informationWHO 2016 CNS TUMOR CLASSIFICATION UPDATE. Arie Perry, M.D. Director, Neuropathology
WHO 2016 CNS TUMOR CLASSIFICATION UPDATE Arie Perry, M.D. Director, Neuropathology DISCLOSURES (Arie Perry, MD) I have no financial relationships to disclose. - and - I will not discuss off label use or
More informationThe 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision
REVIEW ARTICLE doi: 10.2176/nmc.ra.2017-0010 Neurol Med Chir (Tokyo) xx, xxx xxx, xxxx The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision Takashi KOMORI
More informationCNS pathology Third year medical students. Dr Heyam Awad 2018 Lecture 12: CNS tumours 2/3
CNS pathology Third year medical students Dr Heyam Awad 2018 Lecture 12: CNS tumours 2/3 Pilocytic astrocytoma Relatively benign ( WHO grade 1) Occurs in children and young adults Mostly: in the cerebellum
More informationClassification of Diffuse Gliomas: Progress, Pearls and Pitfalls. Rob Macaulay Neuropathologist, MCC October 21, 2017
Classification of Diffuse Gliomas: Progress, Pearls and Pitfalls Rob Macaulay Neuropathologist, MCC October 21, 2017 Objectives Explain why the designation high grade glioma is preferable to GBM for intraoperative
More informationCase Presentation: USCAP Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center
Case Presentation: USCAP 2016 Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center Case History 53 year old female with a long standing history of migraines
More informationIntegrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community
Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community The Harvard community has made this article openly available. Please
More informationH3F3A K27M Mutation in Pediatric CNS Tumors. A Marker for Diffuse High-Grade Astrocytomas
Anatomic Pathology / H3.3 Mutations in Pediatric Diffuse High-Grade Astrocytomas H3F3A K27M Mutation in Pediatric CNS Tumors A Marker for Diffuse High-Grade Astrocytomas Gerrit H. Gielen, MD, 1 Marco Gessi,
More informationThe new WHO 2016 classification of brain tumors what neurosurgeons need to know
DOI 10.1007/s00701-016-3062-3 REVIEW ARTICLE - BRAIN TUMORS The new WHO 2016 classification of brain tumors what neurosurgeons need to know Rouzbeh Banan 1 & Christian Hartmann 1 Received: 8 July 2016
More informationChildhood Brain and Spinal Cord Tumors Treatment Overview (PDQ )
1 di 8 04/03/2017 07.31 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute
More informationMorphological features and genetic alterations
Morphological features and genetic alterations Tutor : Audrey Rousseau Caget Lise: Université d Angers Iorio Vittoria: Seconda Università degli studi di Napoli Manaila Roxana: Iuliu Hatieganu University
More informationDisclaimers. Molecular pathology of brain tumors. Some aspects only. Some details are inevitably personal opinions
Molecular pathology of brain tumors Disclaimers Some aspects only H.K. Ng The Chinese University of Hong Kong Some details are inevitably personal opinions Free ppt : http://www.acp.cuhk.edu.hk/hkng Why
More informationTumours of the Central Nervous System (CNS) Molecular Information Reporting Guide
Sponsored by Tumours of the Central Nervous System (CNS) Molecular Information Reporting Guide Family/Last name Given name(s) Date of birth DD MM YYYY Patient identifiers Date of request Accession/Laboratory
More informationClinical significance of genetic analysis in glioblastoma treatment
Clinical significance of genetic analysis in glioblastoma treatment Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Koji Yoshimoto Can we get prognostic
More informationAnaplastic Pilocytic Astrocytoma: The fusion of good and bad
Anaplastic Pilocytic Astrocytoma: The fusion of good and bad Alexandrina Nikova 1, Charalampos-Chrysovalantis Chytoudis-Peroudis 2, Penelope Korkolopoulou 3 and Dimitrios Kanakis 4 Abstract 5 Pilocytic
More informationSYSTEMIC MANAGEMENT OF PEDIATRIC PRIMARY BRAIN TUMORS
SYSTEMIC MANAGEMENT OF PEDIATRIC PRIMARY BRAIN TUMORS María E. Echevarría, MD Assistant Professor University of Puerto Rico Medical Sciences Campus DISCLOSURES No disclosures INTRODUCTION Pediatric CNS
More informationMOLECULAR DIAGNOSTICS OF GLIOMAS
MOLECULAR DIAGNOSTICS OF GLIOMAS Arie Perry, M.D. Director, Neuropathology Division DIFFUSE GLIOMAS Cell types Astrocytomas (A) Oligodendrogliomas (O) Mixed oligoastrocytoma (MOA) Three WHO grades: II,
More informationEnterprise Interest None
Enterprise Interest None Heterogeneous chromosomal profiles in a unique series of DIPG in children and young adults European Congress of Pathology Amsterdam, 6 th September 2017 Charlotte Dufour, Romain
More informationApplications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities
Wood et al. Diagnostic Pathology (2019) 14:29 https://doi.org/10.1186/s13000-019-0802-8 REVIEW Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular
More informationI have no conflicts of interest in relation to this presentation. Vogel FS & Burger PC 3/28/2016
IF THIS IS NOT GLIOBLASTOMA, THEN WHAT IS IT? Murat Gokden, MD Department of Pathology/Neuropathology University of Arkansas for Medical Sciences Little Rock, AR mgokden@uams.edu I have no conflicts of
More informationLow grade glioma: a journey towards a cure
Editorial Page 1 of 5 Low grade glioma: a journey towards a cure Ali K. Choucair SIU School of Medicine, Springfield, IL, USA Correspondence to: Ali K. Choucair, MD. Professor of Neurology, Director of
More informationWhat yield in the last decade about Molecular Diagnostics in Neuro
What yield in the last decade about Molecular Diagnostics in Neuro Oncology? Raphael Salles S.Medeiros Neuropathologist at HC FMUSP Clinical Research Project Manager at Oncology department at Hospital
More informationCase Report Atypical Presentation of Atypical Teratoid Rhabdoid Tumor in a Child
Case Reports in Oncological Medicine Volume 2013, Article ID 815923, 4 pages http://dx.doi.org/10.1155/2013/815923 Case Report Atypical Presentation of Atypical Teratoid Rhabdoid Tumor in a Child Y. T.
More informationHistopathological Study and Categorisation of Brain Tumors
Histopathological Study and Categorisation of Brain Tumors Ruchira Wadhwa 1*, Purvi Patel 2, Hansa Goswami 3 1 Third Year Resident, 2 Assistant Professor, 3 Professor and Head, Department of Pathology,
More informationKarl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
Expanding on WHO guideline compliant molecular testing of central nervous system tumors by low density whole genome sequencing. Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
More informationDiagnostic application of SNParrays to brain cancers
Diagnostic application of SNParrays to brain cancers Adriana Olar 4/17/2018 No disclosures 55 yo M, focal motor seizure T2 T1-post C DIAGNOSIS BRAIN, LEFT FRONTAL LOBE, BIOPSY: - DIFFUSE GLIOMA, OLIGODENDROGLIAL
More informationNew Imaging Concepts in Central Nervous System Neoplasms
New Imaging Concepts in Central Nervous System Neoplasms Maarten Lequin Department of Pediatric Radiology Wilhelmina Children s Hospital/University Medical Center Utrecht New Imaging Concepts in Central
More informationGeneral: Brain tumors are lesions that have mass effect distorting the normal tissue and often result in increased intracranial pressure.
1 Lecture Objectives Know the histologic features of the most common tumors of the CNS. Know the differences in behavior of the different tumor types. Be aware of the treatment modalities in the various
More informationEffective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific /N 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3
More informationEffective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific Status /N 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9)
More informationIDH1 R132H/ATRX Immunohistochemical validation
IDH1 R132H/ATRX Immunohistochemical validation CIQC/DSM 2016 12 June 2016 0835-0905 Stephen Yip, M.D., Ph.D., FRCPC University of British Columbia Disclosure Statement I have nothing to disclose I will
More informationProtocol Abstract and Schema
Protocol Abstract and Schema A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors Description and
More information2017 Diagnostic Slide Session Case 3
2017 Diagnostic Slide Session Case 3 Andrew Gao, MD Lili-Naz Hazrati, MD, PhD Cynthia Hawkins, MD, PhD Hospital for Sick Children and University of Toronto, Toronto, Canada Disclosures: none Clinical History
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cns_embryonal_tumors
More information2018 ICD-O-3 Updates in Table Format with Annotation for Reference
Status Histology Description (this may be preferred term or a synonym) Report Comments New term 8010 3 Urachal carcinoma (C65.9, C66.9, C67._, C68._) New term 8013 3 Combined large cell neuroendocrine
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More information5-hydroxymethylcytosine loss is associated with poor prognosis for
5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas Feng Zhang 1,*, Yifan Liu 2, Zhiwen Zhang 1, Jie Li 1, Yi Wan 3, Liying Zhang 1, Yangmei
More informationFive Most Common Problems in Surgical Neuropathology
Five Most Common Problems in Surgical Neuropathology If the brain were so simple that we could understand it, we would be so simple that we couldn t Emerson Pugh What is your greatest difficulty in neuropathology?
More informationChildhood Brain and Spinal Cord Tumors Treatment Overview (PDQ )
1 di 14 27/11/2016 17.42 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute
More informationR1601 Essential Immunohistochemical and Molecular Markers for General CNS Glial Tumors
October 22, 2018 12:00-1:00 PM Background The World Health Organization Classification of tumors of the Central Nervous System has recently been revised. There is now greater emphasis on molecular phenotype
More informationSite Specific Coding Rules MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS
Multiple Primary and Histology Site Specific Coding Rules MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways
More informationExamining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationGenomic analysis of childhood High grade glial (HGG) brain tumors
Genomic analysis of childhood High grade glial (HGG) brain tumors Linda D Cooley Children s Mercy, Kansas City The Children s Mercy Hospital, 2017 Genomic analysis of childhood High grade glial (HGG) brain
More informationMALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
More informationSupplemental Information. Molecular, Pathological, Radiological, and Immune. Profiling of Non-brainstem Pediatric High-Grade
Cancer Cell, Volume 33 Supplemental Information Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial Alan Mackay,
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationIDH1 and IDH2 Genetic Testing for Conditions Other Than Myeloid Neoplasms or Leukemia
Medical Policy Manual Genetic Testing, Policy No. 19 IDH1 and IDH2 Genetic Testing for Conditions Other Than Myeloid Neoplasms or Leukemia Next Review: January 2019 Last Review: January 2018 Effective:
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MEDULLOBLASTOMA AND PNET CNS Site Group Medulloblastoma and PNET Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION
More informationPediatric CNS Tumors. Disclosures. Acknowledgements. Introduction. Introduction. Posterior Fossa Tumors. Whitney Finke, MD
Pediatric CNS Tumors Disclosures Whitney Finke, MD Neuroradiology Fellow PGY-6 University of Utah Health Sciences Center Salt Lake City, Utah None Acknowledgements Introduction Nicholas A. Koontz, MD Luke
More informationRapid recurrence of a malignant meningioma: case report
Romanian Neurosurgery Volume XXXI Number 2 2017 April-June Article Rapid recurrence of a malignant meningioma: case report Oguz Baran, Sima Sayyahmeli, Taner Tanriverdi, Pamir Erdincler TURKEY DOI: 10.1515/romneu-2017-0027
More informationUnderstanding general brain tumor pathology, Part I: The basics. Craig Horbinski, M.D., Ph.D. Department of Pathology University of Kentucky
Understanding general brain tumor pathology, Part I: The basics Craig Horbinski, M.D., Ph.D. Department of Pathology University of Kentucky plan of attack what IS a pathologist, anyway? what s so special
More informationCNS TUMORS. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
CNS TUMORS D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) CNS TUMORS The annual incidence of intracranial tumors of the CNS ISmore than intraspinal tumors May be Primary or Secondary
More informationImaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
More information2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:
E-Path A.I. Engine Knowledge Base Enhancements Version 1.0.0.29 April 1, 2018 The major enhancements in the E-Path Knowledge Base from versions 1.0.0.28 through 1.0.0.29 are as follows: 1. Addition/modification
More informationBeyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification
Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification Krishanthan Vigneswaran, Emory University Stewart Neill, Emory University
More informationDiagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants
& 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 1 Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants Nancy M Joseph 1, Joanna Phillips
More informationA clinical perspective on neuropathology and molecular genetics in brain tumors
A clinical perspective on neuropathology and molecular genetics in brain tumors M.J. van den Bent Erasmus MC Cancer Institute Rotterdam, the Netherlands Disclosures Member speakersbureau: MSD Consultancy:
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationAstroblastoma: Radiologic-Pathologic Correlation and Distinction from Ependymoma
AJNR Am J Neuroradiol 23:243 247, February 2002 Case Report Astroblastoma: Radiologic-Pathologic Correlation and Distinction from Ependymoma John D. Port, Daniel J. Brat, Peter C. Burger, and Martin G.
More informationCorporate Medical Policy
Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas
More informationAn Updated Nationwide Epidemiology of Primary Brain Tumors in Republic of Korea, 2013
ORIGINAL ARTICLE Brain Tumor Res Treat 217;5(1):16-23 / pissn 2288-245 / eissn 2288-2413 https://doi.org/1.14791/btrt.217.5.1.16 An Updated Nationwide Epidemiology of Primary Brain Tumors in Republic of
More informationGenomic Analysis in the Practice of Surgical Neuropathology. The Emory Experience
Genomic Analysis in the Practice of Surgical Neuropathology The Emory Experience Stewart G. Neill, MD; Debra F. Saxe, PhD; Michael R. Rossi, PhD; Matthew J. Schniederjan, MD; Daniel J. Brat, MD, PhD The
More informationTumors of the Central Nervous System
Tumors of the Central Nervous System 1 Financial Disclosures I have NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT Introduction General: Brain tumors are lesions that have mass effect
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More information2019 Neoplasms of the BRAIN/CNS. CDC & Florida DOH Attribution
2019 Neoplasms of the BRAIN/CNS 2018-2019 FCDS Educational Webcast Series Steven Peace, BS, CTR March 21, 2019 CDC & Florida DOH Attribution Funding for this conference was made possible (in part) by the
More informationSUPPLEMENTARY INFORMATION
VOLUME: 1 ARTICLE NUMBER: 0027 In the format provided by the authors and unedited. Rapid intraoperative histology of unprocessed surgical specimens via fibre-laser-based stimulated Raman scattering microscopy
More informationEmbryonal tumor with multilayered rosettes, C19MC-altered: Report of an extremely rare malignant pediatric central nervous system neoplasm
745208SCO0010.1177/2050313X17745208SAGE Open Medical Case ReportsTariq et al. case-report2017 Case Report SAGE Open Medical Case Reports Embryonal tumor with multilayered rosettes, C19MC-altered: Report
More informationSTUDY OFPAEDIATRIC CNS TUMORS IN TERTIARY CARE CENTER
IJCRR Section: Healthcare Sci. Journal Impact Factor 4.016 Original Article STUDY OFPAEDIATRIC CNS TUMORS IN TERTIARY CARE CENTER Grishma P. Jobanputra Tutor, Department of Pathology, B.J. Medical College,
More informationDNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
Paul et al. Clinical Epigenetics (2017) 9:32 DOI 10.1186/s13148-017-0331-9 RESEARCH Open Access DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas Yashna Paul, Baisakhi
More informationAMERICAN ASSOCIATION OF NEUROPATHOLOGISTS COMPANION SOCIETY MEETING at the 106 th ANNUAL MEETING OF THE USCAP San Antonio, March 4, 2017
AMERICAN ASSOCIATION OF NEUROPATHOLOGISTS COMPANION SOCIETY MEETING at the 106 th ANNUAL MEETING OF THE USCAP San Antonio, March 4, 2017 SYLLABUS Papillary Tumor of the Pineal Region and the Differential
More informationEpendymomas: Prognostic Factors and Outcome Analysis in a Retrospective Series of 33 Patients
ORIGINAL ARTICLE Brain Tumor Res Treat 2017;5(2):70-76 / pissn 2288-2405 / eissn 2288-2413 https://doi.org/10.14791/btrt.2017.5.2.70 Ependymomas: Prognostic Factors and Outcome Analysis in a Retrospective
More informationCase 1. Maysa Al-Hussaini MD FRCPath
Case 1 Maysa Al-Hussaini MD FRCPath MAYSA King AL-HUSSAINI Hussein Cancer MD Center MRCPATH KING HUSSEIN Amman CANCER Jordan CENTER Clinical history 4 year old boy History of frontal headache, sleepiness.
More informationPathologic Analysis of CNS Surgical Specimens
2015 Kenneth M. Earle Memorial Neuropathology Review Pathologic Analysis of CNS Surgical Specimens Peter C. Burger, MD Interdisciplinary Quality Control Familiarity with entities Use of diagnostic algorithm
More informationHistopathological Spectrum of Central Nervous System Tumors: A Single Centre Study of 100 Cases
Original Article DOI: 10.17354/ijss/2015/408 Histopathological Spectrum of Central Nervous System Tumors: A Single Centre Study of 100 Cases Sarita Nibhoria 1, Kanwardeep Kaur Tiwana 1, Richa Phutela 2,
More informationAdult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2015 Adult IDH wild type astrocytomas biologically and clinically resolve into
More informationWHO 2016 CNS What have we learnt for the future?
WHO 2016 CNS What have we learnt for the future? H.K. Ng Free ppt at http://www.acp.cuhk.edu.hk/hkng Louis DN & Ellison DW et al., 2016 H K, how can we cope with the new molecular requirements in the WHO?
More informationATRX loss refines the classification of anaplastic gliomas and identifies a. subgroup of IDH mutant astrocytic tumors with better prognosis
Wiestler et al. 1 ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis Benedikt Wiestler 1,4, David Capper 2,5, Tim
More informationPracticing Pathology in the Era of. Molecular Classification and Precision Medicine. Molecular Classification
Practicing Pathology in the Era of Molecular Classification August 18, 2016 Molecular Classification and Precision Medicine Liang Cheng, MD Indiana University Indianapolis, IN liang_cheng@yahoo.com Sept
More informationOver the last 30 years, widespread efforts to characterize
GALANIS ET AL Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice Evanthia Galanis, MD, Farhad Nassiri, MD, Shannon Coy, MD, Romina Nejad, HBSc, MSc (C), Gelareh Zadeh, MD, PhD, and Sandro
More informationCase Report IDH1 R132H mutation in a pilocytic astrocytoma: a case report
Int J Clin Exp Pathol 2015;8(9):11809-11813 www.ijcep.com /ISSN:1936-2625/IJCEP0012939 Case Report IDH1 R132H mutation in a pilocytic astrocytoma: a case report Felix Behling 1, Julia Steinhilber 2, Marcos
More informationCynthia Hawkins. Division of Pathology, Labatt Brain Tumour Research Centre, The Hospital for Sick Children, University of Toronto, Canada
Cynthia Hawkins Division of Pathology, Labatt Brain Tumour Research Centre, The Hospital for Sick Children, University of Toronto, Canada To apply a practical diagnostic approach to pediatric high grade
More informationAnna Maria Buccoliero Department of Biomedicine, Careggi Hospital Florence
PEDIATRIC RHABDOID MENINGIOMA Anna Maria Buccoliero Department of Biomedicine, Careggi Hospital Florence CLINICAL HISTORY A 3-year-old boy, with a recent history of seizures, was admitted to the Neurosurgery
More informationATRX and IDH1 R132H immunohistochemistry with subsequent copy number analysis and IDH
Acta Neuropathol (2015) 129:133 146 DOI 10.1007/s00401-014-1370-3 ORIGINAL PAPER ATRX and IDH1 R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an integrated
More informationTumors of the Nervous System
Tumors of the Nervous System Peter Canoll MD. PhD. What I want to cover What are the most common types of brain tumors? Who gets them? How do they present? What do they look like? How do they behave? 1
More informationIn 1988 Dumas-Duport et al. first used
Copyright 2009, Barrow Neurological Institute Dysembryoplastic Neuroepithelial Tumor: A Review Mark Garrett, MD Jennifer Eschbacher, MD Peter Nakaji, MD Most DNETs are benign, low-grade lesions. However,
More informationConditional survival after a diagnosis of malignant brain tumour in Canada:
ORIGINAL ARTICLE BRAIN CANCER CONDITIONAL SURVIVAL PROBABILITIES: 2000 2008, Yuan et al. Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000 2008 Y. Yuan phd,* J. Ross mph,*
More informationDual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?
Journal of Neuropatholgy & Experimental Neurology Vol. 0, No. 0, 2017, pp. 1 5 doi: 10.1093/jnen/nlx024 BRIEF REPORT Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma
More informationReview: Diagnostic, prognostic and predictive relevance of molecular markers in gliomas
Review: Diagnostic, prognostic and predictive relevance of molecular markers in gliomas Sebastian Brandner MD FRCPath 1 and Andreas von Deimling 2 MD 1) Division of Neuropathology, The National Hospital
More informationGliomatosis cerebri: no evidence for a separate brain tumor entity
DOI 10.1007/s00401-015-1495-z ORIGINAL PAPER Gliomatosis cerebri: no evidence for a separate brain tumor entity Ulrich Herrlinger 1 David T. W. Jones 2,3 Martin Glas 1,4 Elke Hattingen 5 Dorothee Gramatzki
More informationPrecision medicine: How to exploit the growing knowledge on the evolving genomes of cells to improve cancer prevention and therapy.
Precision medicine: How to exploit the growing knowledge on the evolving genomes of cells to improve cancer prevention and therapy Joe Costello, PhD Department of Neurological Surgery A more accurate and
More informationOligodendrogliomas & Oligoastrocytomas
Oligodendrogliomas & Oligoastrocytomas ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely
More informationSurgical resection versus watchful waiting in low-grade gliomas
Annals of Oncology 28: 1942 1948, 217 doi:1.193/annonc/mdx23 Published online 5 May 217 ORIGINAL ARTICLE Surgical resection versus watchful waiting in low-grade gliomas A. S. Jakola 1,2,3 *, A. J. Skjulsvik
More information